CD7 and acute lymphoblastic leukemia: Early results of the first-in-human clinical trial (NCT04004637) utilizing allogeneic CD7NKCAR-Ts in patients with CD7+R/R T-ALL or T-cell lymphoblastic lymphoma pre- or post-HSCT were recently reported [70].